Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2012
11/01/2012US20120276182 Methods of treating fungal, yeast and mold infections
11/01/2012US20120276180 Active Agent Delivery and/or Odor Retentive Composition and Methods of Use Thereof
11/01/2012US20120276171 Micelle encapsulation of therapeutic agents
11/01/2012US20120276170 Injectable drug carrier comprising layered double hydroxide
11/01/2012US20120276169 Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy
11/01/2012US20120276168 Amino acid conjugates of quetiapine, process for making and using the same
11/01/2012US20120276166 Elution-stabilized preparation
11/01/2012US20120276164 Implantable paste and its use
11/01/2012US20120276163 Anti-cancer composition comprising alginate
11/01/2012US20120276162 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
11/01/2012US20120276153 Use of aerosolized levofloxacin for treating cystic fibrosis
11/01/2012US20120276152 Systems and methods of using zinc-chelator to treat myocardial infarction
11/01/2012US20120276151 Drug delivery from embolic agents
11/01/2012US20120276148 Adenoviral vector vaccine
11/01/2012US20120276147 Ctsp cancer-testis antigens
11/01/2012US20120276142 Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same
11/01/2012US20120276126 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
11/01/2012US20120276124 Maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
11/01/2012US20120276121 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
11/01/2012US20120276114 Ifn-gamma inhibitors in the treatment of motoneuron diseases
11/01/2012US20120276111 Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
11/01/2012US20120276108 Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
11/01/2012US20120276105 Use of cytokine expression to predict skin inflammation; methods of treatment
11/01/2012US20120276093 Therapeutic combination comprising a cdc7 inhibitor and an anti-neoplastic agent
11/01/2012US20120276088 Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
11/01/2012US20120276087 Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
11/01/2012US20120276078 Glycosidase enzymes
11/01/2012US20120276076 Arf6 as a new target for treating alzheimer's disease
11/01/2012US20120276072 Constructs for expressing lysosomal polypeptides
11/01/2012US20120276069 Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers
11/01/2012US20120276064 Methods and compositions for rejuvenation and expansion of stem cells
11/01/2012US20120276060 Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease
11/01/2012US20120276059 Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease
11/01/2012US20120276051 Inhibitors of hepatitis c virus
11/01/2012US20120276050 Methods and compositions of treating a flaviviridae family viral infection
11/01/2012US20120276047 Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
11/01/2012US20120276045 Treatment of solid cancers
11/01/2012US20120276041 Conformable solvent-based bandage and coating material
11/01/2012US20120276039 Aptamer-modified polymeric materials for the binding of factors in a wound environment
11/01/2012US20120276018 Alkaloid ester and carbamate derivatives and medicinal compositions thereof
11/01/2012US20120276017 Methods and Compositions for Treatment of Attention Deficit Disorder
11/01/2012US20120276012 Method of Treatment and Screening Method
11/01/2012US20120276009 Pharmaceutical composition
11/01/2012US20120275998 Biodegradable stent comprising an acid scavenging agent
11/01/2012CA2841452A1 Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
11/01/2012CA2834735A1 Method of treating dyskinesia
11/01/2012CA2834680A1 Selecting use of proteasome inhibitors based on nf-kb2 sequence
11/01/2012CA2834619A1 Controlled release of immunosuppressants from synthetic nanocarriers
11/01/2012CA2834588A1 Method for determining clinically relevant hypoxia in cancer
11/01/2012CA2834571A1 Tolerogenic synthetic nanocarriers for inducing regulatory b cells
11/01/2012CA2834548A1 Inhibitors of histone deacetylase
11/01/2012CA2834534A1 Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cells
11/01/2012CA2834533A1 Tolerogenic synthetic nanocarriers for allergy therapy
11/01/2012CA2834532A1 Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
11/01/2012CA2834527A1 Tolerogenic synthetic nanocarriers to reduce antibody responses
11/01/2012CA2834519A1 Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
11/01/2012CA2834514A1 Tolerogenic synthetic nanocarriers
11/01/2012CA2834467A1 Alkaloid ester and carbamate derivatives and medicinal compositions thereof
11/01/2012CA2834465A1 Cyclic amide derivative
11/01/2012CA2834452A1 Derivatives of n- [( 1h - pyrazol - 1 - yl) aryl] - 1h - indole or 1h - indazole - 3 - carboxamide, their preparation and their use as p2y12 antagonists
11/01/2012CA2834429A1 5-membered ring aromatic heterocyclic derivative having npy y5 receptor antagonistic activity
11/01/2012CA2834417A1 Novel 3-hydroxyisothiazole 1-oxide derivative
11/01/2012CA2834387A1 Novel rock inhibitors
11/01/2012CA2834355A1 Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
11/01/2012CA2834343A1 Disorders implicating pufa oxidation
11/01/2012CA2834342A1 Impaired energy processing disorders and mitochondrial deficiency
11/01/2012CA2834341A1 Oxidative retinal diseases
11/01/2012CA2834282A1 Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
11/01/2012CA2834280A1 Methods of administering anatabine to treat autism spectrum disorders and seizure disorders
11/01/2012CA2834274A1 Neurodegenerative disorders and muscle diseases implicating pufas
11/01/2012CA2834255A1 Peptide for inducing regeneration of tissue and use thereof
11/01/2012CA2834232A1 Modulation of apolipoprotein ciii (apociii) expression
11/01/2012CA2834224A1 17a-hydroxylase/c17,20-lyase inhibitors
11/01/2012CA2834212A1 Layer processing for pharmaceuticals
11/01/2012CA2834200A1 A method for manufacturing pegylated oligonucleotides
11/01/2012CA2834166A1 Bicyclic pyridazine compounds as pim inhibitors
11/01/2012CA2834063A1 Administration of iloprost as aerosol bolus
11/01/2012CA2834049A1 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
11/01/2012CA2834042A1 Acute cognitive and mood effects of plant polysaccharides in adult human subjects
11/01/2012CA2834040A1 Intravascular delivery of nanoparticle compositions and uses thereof
11/01/2012CA2834028A1 Stable pharmaceutical composition
11/01/2012CA2833963A1 Novel compound useful for the treatment of degenerative and inflammatory diseases
11/01/2012CA2833962A1 Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
11/01/2012CA2833942A1 Novel compound useful for the treatment of degenerative and inflammatory diseases
11/01/2012CA2833806A1 Method for treatment of macular degeneration by modulating p2y12 or p2x7 receptors
11/01/2012CA2833592A1 Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
11/01/2012CA2833493A1 Amide compound and pharmaceutical application therefor
11/01/2012CA2833443A1 A composition of entacopone
11/01/2012CA2833420A1 Oxymetazoline for the treatment of ano-rectal disorders
11/01/2012CA2833390A1 Hsp90 combination therapy
11/01/2012CA2833385A1 Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
11/01/2012CA2833304A1 Salt of an inhibitor of phoshodiesterase 10 enzyme
11/01/2012CA2833121A1 Novel cephem compound having catechol or pseudo-catechol structure
11/01/2012CA2833115A1 Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
11/01/2012CA2832996A1 Aldosterone synthase inhibitors
11/01/2012CA2832693A1 Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
11/01/2012CA2832663A1 Risperidone sustained release microsphere composition
11/01/2012CA2832342A1 Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
11/01/2012CA2829171A1 Pyrazolidin-3-one derivatives
11/01/2012CA2829170A1 Ethynyl derivatives as positive allosteric modulators of the mglur5
1 ... 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 ... 7860